# Safety and Tolerability of Z-100 in Patients With Early HIV Infection

> **NCT00016692** · PHASE1 · TERMINATED · sponsor: **Zeria Pharmaceutical**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Z-100

## Key facts

- **NCT ID:** NCT00016692
- **Lead sponsor:** Zeria Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2006-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00016692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00016692, "Safety and Tolerability of Z-100 in Patients With Early HIV Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00016692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*